Several studies have shown that minocycline, a semisynthetic, second-generation tetracycline derivative, is neuroprotective in animal models of central nervous system trauma and several neurodegenerative diseases. Common to all these reports are the beneficial effects of minocycline in reducing neural inflammation and preventing cell death. Here, the authors review the proposed mechanisms of action of minocycline and suggest that minocycline may inhibit several aspects of the inflammatory response and prevent cell death through the inhibition of the p38 mitogen-activated protein kinase pathway, an important regulator of immune cell function and cell death.
Alarcon GS. 2000. Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs9(7):1491-1498.
2.
Alvarado-Kristensson M, Melander F, Leandersson K, Ronnstrand L, Wernstedt C, Andersson T.2004. p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med199(4):449-458.
3.
Ambrosini E, Aloisi F.2004. Chemokines and glial cells: a complex network in the central nervous system. Neurochem Res29(5):1017-1038.
4.
Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, and others. 1996. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A93(24):14014-14019.
5.
Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB. 1997. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett410(2-3):259-264.
6.
Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. 2002. Minocycline markedly protects the neonatal brain against hypoxicischemic injury. Ann Neurol52(1):54-61.
7.
Bao F, Chen Y, Dekaban GA, Weaver LC. 2004. Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. J Neurochem in press.
8.
Bartholdi D, Schwab ME. 1997. Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci9(7):1422-1438.
9.
Beattie MS, Harrington AW, Lee R, Kim JY, Boyce SL, Longo FM, and others. 2002. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron36(3):375-386.
10.
Beattie MS, Hermann GE, Rogers RC, Bresnahan JC. 2002. Cell death in models of spinal cord injury. Prog Brain Res137:37-47.
11.
Bethea JR. 2000. Spinal cord injury-induced inflammation: a dualedged sword. Prog Brain Res128:33-42.
12.
Bhat NR, Zhang P, Lee JC, Hogan EL. 1998. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci18(5):1633-1641.
13.
Blight AR. 1985. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma2(4):299-315.
14.
Blight AR. 1994. Effects of silica on the outcome from experimental spinal cord injury: implication of macrophages in secondary tissue damage. Neuroscience60(1):263-273.
15.
Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. 2002. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain125(Pt 6):1297-1308.
16.
Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, and others. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med6(7):797-801.
17.
Cregan SP, Dawson VL, Slack RS. 2004. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene23(16):2785-2796.
18.
Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beattie MS. 1997. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med3(1):73-76.
19.
David S.2002. Recruiting the immune response to promote long distance axon regeneration after spinal cord injury. Prog Brain Res137:407-414.
Diguet E, Gross CE, Tison F, Bezard E.2004. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Exp Neurol189(1):1-4.
22.
Dong C, Davis RJ, Flavell RA. 2002. MAP kinases in the immune response. Annu Rev Immunol20:55-72.
23.
Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, and others. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci U S A98(25):14669-14674.
24.
Dusart I, Schwab ME. 1994. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci6(5):712-724.
25.
Ekshyyan O, Aw TY. 2004. Apoptosis in acute and chronic neurological disorders. Front Biosci9:1567-1576.
26.
Estelles A, Charlton CA, Blau HM. 1999. The phosphoprotein protein PEA-15 inhibits Fas but increases TNF-R1-mediated caspase-8 activity and apoptosis. Dev Biol216(1):16-28.
27.
Feldman S, Careccia RE, Barham KL, Hancox J.2004. Diagnosis and treatment of acne. Am Fam Physician69(9):2123-2130.
28.
Hains BC, Black JA, Waxman SG. 2003. Primary cortical motor neurons undergo apoptosis after axotomizing spinal cord injury. J Comp Neurol462(3):328-341.
29.
Hausmann ON. 2003. Post-traumatic inflammation following spinal cord injury. Spinal Cord41(7):369-378.
30.
He Y, Appel S, Le W.2001. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res909(1-2):187-193.
31.
He Y, Yu W, Baas PW. 2002. Microtubule reconfiguration during axonal retraction induced by nitric oxide. J Neurosci22(14):5982-5991.
32.
Hermann GE, Rogers RC, Bresnahan JC, Beattie MS. 2001. Tumor necrosis factor-alpha induces cFOS and strongly potentiates glutamate-mediated cell death in the rat spinal cord. Neurobiol Dis8(4):590-599.
33.
Hersch S, Fink K, Vonsattel JP, Friedlander RM. 2003. Minocycline is protective in a mouse model of Huntington’s disease. Ann Neurol54(6):841; author reply 842-3.
34.
Hida H, Nagano S, Takeda M, Soliven B.1999. Regulation of mitogen-activated protein kinases by sphingolipid products in oligodendrocytes. J Neurosci19(17):7458-7467.
35.
Horiuchi H, Ogata T, Morino T, Chuai M, Yamamoto H.2003. Continuous intrathecal infusion of SB203580, a selective inhibitor of p38 mitogen-activated protein kinase, reduces the damage of hind-limb function after thoracic spinal cord injury in rat. Neurosci Res47(2):209-217.
36.
Karpus WJ, Kennedy KJ. 1997. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol62(5): 681-687.
37.
Kaufmann SH, Hengartner MO. 2001. Programmed cell death: alive and well in the new millennium. Trends Cell Biol11(12):526-534.
38.
Kikuchi M, Tenneti L, Lipton SA. 2000. Role of p38 mitogen-activated protein kinase in axotomy-induced apoptosis of rat retinal ganglion cells. J Neurosci20(13):5037-5044.
39.
Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W.2004. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res27(3):314-318.
40.
Klein NC, Cunha BA. 1995. Tetracyclines. Med Clin North Am79(4):789-801.
41.
Koistinaho M, Koistinaho J.2002. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia40(2):175-183.
42.
Kremlev SG, Roberts RL, Palmer C.2004. Differential expression of chemokines and chemokine receptors during microglial activation and inhibition. J Neuroimmunol149(1-2):1-9.
43.
Kriz J, Nguyen MD, Julien JP. 2002. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis10(3):268-278.
44.
Kumar S, Boehm J, Lee JC. 2003. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov2(9):717-726.
45.
Kwon BK, Liu J, Messerer C, Kobayashi NR, McGraw J, Oschipok L, Tetzlaff W.2002. Survival and regeneration of rubrospinal neurons 1 year after spinal cord injury. Proc Natl Acad Sci U S A99(5):3246-3251.
46.
Lacroix S, Chang L, Rose-John S, Tuszynski MH. 2002. Delivery of hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infiltration and inhibits axonal growth. J Comp Neurol454(3):213-228.
47.
Lee SM, Yune TY, Kim SJ, Kim YC, Oh YJ, Markelonis GJ, Oh TH. 2004. Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. J Neurochem91(3):568-578.
48.
Lee SM, Yune TY, Kim SJ, Park do W, Lee YK, Kim YC, and others. 2003. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma20(10):1017-1027.
49.
Lee YB, Schrader JW, Kim SU. 2000. p38 map kinase regulates TNF-alpha production in human astrocytes and microglia by multiple mechanisms. Cytokine12(7):874-880.
50.
Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y.2001. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett315(1-2):61-64.
51.
Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, and others. 1997. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci17(14):5395-5406.
McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP. 1998. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med4(3):291-297.
54.
McPhail LT, Stirling DP, Tetzlaff W, Kwiecien JM, Ramer MS. 2004. The contribution of activated phagocytes and myelin degeneration to axonal retraction/dieback following spinal cord injury. Eur J Neurosci20(8):1984-1994.
55.
Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, and others. 2004. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol55(5):756.
Park SY, Lee H, Hur J, Kim SY, Kim H, Park JH, and others. 2002. Hypoxia induces nitric oxide production in mouse microglia via p38 mitogen-activated protein kinase pathway. Brain Res Mol Brain Res107(1):9-16.
58.
Parks WC, Wilson CL, Lopez-Boado YS. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol4(8):617-629.
59.
Piao CS, Kim JB, Han PL, Lee JK. 2003. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J Neurosci Res73(4):537-544.
60.
Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. 2002. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol51(2):215-223.
61.
Popovich PG. 2000. Immunological regulation of neuronal degeneration and regeneration in the injured spinal cord. Prog Brain Res128:43-58.
62.
Popovich PG, Guan Z, McGaughy V, Fisher L, Hickey WF, Basso DM. 2002. The neuropathological and behavioral consequences of intraspinal microglial/macrophage activation. J Neuropathol Exp Neurol61(7):623-633.
63.
Popovich PG, Guan Z, Wei P, Huitinga I, van Rooijen N, Stokes BT. 1999. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp Neurol158(2):351-365.
64.
Power C, Henry S, Del Bigio MR, Larsen PH, Corbett D, Imai Y, and others. 2003. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol53(6):731-742.
65.
Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G.1995. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci U S A92(24): 11294-11298.
66.
Pruzanski W, Greenwald RA, Street IP, Laliberte F, Stefanski E, Vadas P.1992. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol44(6):1165-1170.
67.
Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, and others. 1998. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med4:814-821.
68.
Rincon M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, and others. 1998. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. Embo J17(10):2817-2829.
69.
Rincon M, Pedraza-Alva G.2003. JNK and p38 MAP kinases in CD4+ and CD8+ T cells. Immunol Rev192:131-142.
70.
Ryu JK, Franciosi S, Sattayaprasert P, Kim SU, McLarnon JG. 2004. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia48(1):85-90.
71.
Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. 2001. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery48(6):1393-1399; discussion 1399-401.
72.
Scarabelli TM, Stephanou A, Pasini E, Gitti G, Townsend P, Lawrence K, and others. 2004. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol43(5):865-874.
73.
Schutyser E, Struyf S, Van Damme J.2003. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev14(5):409-426.
74.
Schwab ME, Bartholdi D.1996. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev76(2):319-370.
75.
Shuman SL, Bresnahan JC, Beattie MS. 1997. Apoptosis of microglia and oligodendrocytes after spinal cord contusion in rats. J Neurosci Res50(5):798-808.
76.
Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z.2004. Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport15(14):2181-2184.
77.
Springer JE, Azbill RD, Knapp PE. 1999. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat Med5(8):943-946.
78.
Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, Nikolic-Paterson DJ. 2003. Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol14(2):338-351.
79.
Stirling DP, Plunet, W, Khodarahmi, K, Liu, J, Becker KG, Dyer JK, and others. 2003. Minocycline treatment reduces p38 MAP Kinase expression within microglia/macrophages and improves functional outcome after spinal cord injury. Program No. 76.9. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience.
80.
Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, and others. 2004. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci24(9): 2182-2190.
81.
Streit WJ, Semple-Rowland SL, Hurley SD, Miller RC, Popovich PG, Stokes BT. 1998. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol152(1):74-87.
82.
Suk K.2004. Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci Lett366(2):167-171.
83.
Suzuki K, Hino M, Hato F, Tatsumi N, Kitagawa S.1999. Cytokine-specific activation of distinct mitogen-activated protein kinase sub-type cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha. Blood93(1):341-349.
84.
Taoka Y, Okajima K.2000. Role of leukocytes in spinal cord injury in rats. J Neurotrauma17(3):219-229.
85.
Taoka Y, Okajima K, Murakami K, Johno M, Naruo M.1998. Role of neutrophil elastase in compression-induced spinal cord injury in rats. Brain Res799(2):264-269.
86.
Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, and others. 2004. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A101(9):3071-3076.
87.
Thomas M, Le WD. 2004. Minocycline: neuroprotective mechanisms in Parkinson’s disease. Curr Pharm Des10(6):679-686.
88.
Thomas M, Le WD, Jankovic J.2003. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson’s disease and Huntington’s disease. Clin Neuropharmacol26(1):18-23.
89.
Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J.2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci21(8):2580-2588.
90.
Tikka TM, Koistinaho JE. 2001. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol166(12):7527-7533.
91.
Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W.2002. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport13(8):1067-1070.
92.
Viviani B, Bartesaghi S, Corsini E, Galli CL, Marinovich M.2004. Cytokines role in neurodegenerative events. Toxicol Lett149(1-3):85-89.
93.
Wada T, Penninger JM. 2004. Mitogen-activated protein kinases in apoptosis regulation. Oncogene23(16):2838-2849.
94.
Wang CX, Yang T, Shuaib A.2003. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res963(1-2):327-329.
95.
Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z.2004. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem279(19):19948-19954.
96.
Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, and others. 2003. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington’s disease. Proc Natl Acad Sci U S A100(18):10483-10487.
97.
Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. 2003. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain126(Pt 7):1628-1637.
98.
Wells JE, Rice TK, Nuttall RK, Edwards DR, Zekki H, Rivest S, Yong VW. 2003. An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J Neurosci23(31):10107-10115.
99.
Williams AS, Mizuno M, Richards PJ, Holt DS, Morgan BP. 2004. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum50(9):3035-3044.
100.
Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, and others. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci22(5):1763-1771.
101.
Wu KL, Chan SH, Chao YM, Chan JY. 2003. Expression of pro-inflammatory cytokine and caspase genes promotes neuronal apoptosis in pontine reticular formation after spinal cord transection. Neurobiol Dis14(1):19-31.
102.
Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, and others. 2004. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol4(1):7.
103.
Yong VW. 2004. Prospects for neuroprotection in multiple sclerosis. Front Biosci9:864-872.
104.
Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. 2004. The promise of minocycline in neurology. Lancet Neurol3(12):744-751.
105.
Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J.1998. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A95(26):15769-15774.
106.
Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J.1999. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A96(23):13496-13500.
107.
Zhang SC, Goetz BD, Duncan ID. 2003. Suppression of activated microglia promotes survival and function of transplanted oligodendroglial progenitors. Glia41(2):191-198.
108.
Zhang W, Narayanan M, Friedlander RM. 2003. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol53(2):267-270.
109.
Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, and others. 2002. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature417(6884):74-78.
110.
Zu YL, Qi J, Gilchrist A, Fernandez GA, Vazquez-Abad D, Kreutzer DL, and others. 1998. p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-alpha or FMLP stimulation. J Immunol160(4):1982-1989.
